Icon Plc Forecasted to Post Q4 2017 Earnings of $1.41 Per Share (ICLR)
Icon Plc (NASDAQ:ICLR) – Equities researchers at KeyCorp upped their Q4 2017 earnings per share estimates for shares of Icon Plc in a research report issued on Sunday. KeyCorp analyst D. Hooker now forecasts that the medical research company will earn $1.41 per share for the quarter, up from their prior estimate of $1.40. KeyCorp currently has a “Overweight” rating and a $125.00 target price on the stock. KeyCorp also issued estimates for Icon Plc’s Q1 2018 earnings at $1.42 EPS, Q2 2018 earnings at $1.47 EPS, Q3 2018 earnings at $1.52 EPS, Q4 2018 earnings at $1.56 EPS, FY2018 earnings at $5.97 EPS and FY2019 earnings at $5.89 EPS.
Icon Plc (NASDAQ:ICLR) last released its quarterly earnings results on Thursday, October 26th. The medical research company reported $1.35 EPS for the quarter, topping the consensus estimate of $1.32 by $0.03. The company had revenue of $440.30 million for the quarter, compared to analyst estimates of $438.09 million. Icon Plc had a return on equity of 28.42% and a net margin of 16.37%. The firm’s revenue was up 4.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.19 earnings per share.
A number of other research analysts have also issued reports on ICLR. Mizuho boosted their target price on Icon Plc from $104.00 to $108.00 and gave the company a “neutral” rating in a report on Thursday, July 27th. Credit Suisse Group restated a “buy” rating on shares of Icon Plc in a research note on Friday, July 28th. Jefferies Group LLC restated a “buy” rating on shares of Icon Plc in a research note on Sunday, July 30th. SunTrust Banks, Inc. upgraded Icon Plc from a “hold” rating to a “buy” rating and lifted their price target for the company from $93.00 to $126.00 in a research note on Monday, July 31st. Finally, Zacks Investment Research downgraded Icon Plc from a “buy” rating to a “hold” rating in a research note on Friday, August 18th. Four equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $121.00.
Icon Plc (NASDAQ:ICLR) opened at $113.24 on Tuesday. The stock has a market capitalization of $6,163.04, a P/E ratio of 21.84, a PEG ratio of 1.76 and a beta of 0.56. The company has a quick ratio of 1.90, a current ratio of 1.90 and a debt-to-equity ratio of 0.31. Icon Plc has a twelve month low of $73.76 and a twelve month high of $124.48.
A number of institutional investors have recently added to or reduced their stakes in ICLR. Koch Industries Inc. increased its stake in Icon Plc by 17,508.8% in the second quarter. Koch Industries Inc. now owns 666,140 shares of the medical research company’s stock valued at $659,000 after purchasing an additional 662,357 shares during the last quarter. FMR LLC increased its stake in Icon Plc by 38.4% during the second quarter. FMR LLC now owns 2,291,005 shares of the medical research company’s stock worth $224,037,000 after acquiring an additional 635,950 shares during the last quarter. Janus Henderson Group PLC increased its stake in Icon Plc by 48.4% during the second quarter. Janus Henderson Group PLC now owns 1,068,159 shares of the medical research company’s stock worth $104,488,000 after acquiring an additional 348,292 shares during the last quarter. Mckinley Capital Management LLC Delaware increased its stake in Icon Plc by 2,674.8% during the second quarter. Mckinley Capital Management LLC Delaware now owns 338,520 shares of the medical research company’s stock worth $33,104,000 after acquiring an additional 326,320 shares during the last quarter. Finally, Principal Financial Group Inc. increased its stake in Icon Plc by 71.5% during the third quarter. Principal Financial Group Inc. now owns 768,471 shares of the medical research company’s stock worth $87,513,000 after acquiring an additional 320,356 shares during the last quarter. Hedge funds and other institutional investors own 91.59% of the company’s stock.
Icon Plc Company Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Receive News & Stock Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related stocks with our FREE daily email newsletter.